VEGFA and ovarian carcinoma: These results suggest that targeting the VEGF pathway or simultaneously targeting the VEGF and B cell activation pathway seem like rational choices for ovarian cancer subtype 2 patients, which have a shorter survival time compared with ovarian cancer subtype 1 patients.